泰国真实临床实践中Xpert MTB/RIF检测的应用评估
结果显示该检测在涂片阳性培养阳性病例中灵敏度100%,涂片阴性培养阳性中81%,特异度95.7%。结论认为Xpert MTB/RIF是诊断肺结核的有效工具,对涂片阴性患者和高利福平耐药流行区更具成本效益。
要点
- Xpert MTB/RIF在涂片阳性培养阳性肺结核中灵敏度为100%,涂片阴性培养阳性为81%。
- 该检测特异度为95.7%,在培养阴性但临床诊断肺结核中灵敏度37.8%、阳性预测值83.8%。
- 59%痰量少的病例需离心处理,离心可能提高Xpert MTB/RIF的检出率。
核心结论
- Xpert MTB/RIF是诊断肺结核的有效工具,对涂片阴性患者和高利福平耐药流行区更具成本效益。
- 早期诊断结核有利于早期治疗并实施限制结核传播的策略。
研究设计与样本
- 前瞻性研究,在泰国3家大型三级医院开展,纳入疑似肺结核患者。
- 痰标本送检涂片染色、分枝杆菌培养和Xpert MTB/RIF检测。
主要发现
- 在培养阳性病例中,Xpert MTB/RIF在涂片阳性组灵敏度100%,涂片阴性组灵敏度81%。
- Xpert MTB/RIF特异度为95.7%。
- 在培养阴性但临床诊断肺结核的病例中,Xpert MTB/RIF灵敏度37.8%,阳性预测值83.8%。
- 59%痰量少的病例需要离心处理。
- 5例假阳性见于非结核分枝杆菌、陈旧性肺结核瘢痕和免疫重建综合征患者。
临床怎么用
- Xpert MTB/RIF可用于疑似肺结核患者的痰标本检测,尤其适用于涂片阴性患者和高利福平耐药流行区。
- 痰量少时可行离心处理以提高Xpert MTB/RIF检出率。
- 对Xpert MTB/RIF与MGIT利福平药敏结果不一致的病例,可用rpoB基因测序确认。
局限性
- 在培养阴性但临床诊断肺结核的病例中Xpert MTB/RIF灵敏度较低(37.8%)。
- 存在假阳性情况,见于非结核分枝杆菌、陈旧性肺结核瘢痕和免疫重建综合征患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delayed diagnosis of tuberculosis (TB) and drug-resistant TB are major challenges of TB control in Thailand. This study assessed the practicality of the Xpert MTB/RIF assay in a real-life setting with high prevalence of human immunodeficiency virus (HIV) infection and pulmonary tuberculosis (PTB). METHODS: This prospective study was conducted at 3 large tertiary care hospitals. Patients who had suspected PTB were enrolled into the study. Expectorated sputum samples were sent for staining, mycobacterial culture, and Xpert MTB/RIF. RESULTS: Four hundred ninety-four patients were enrolled. From 355 cases with final diagnosis of PTB, 263 (71.8%) had definite diagnosis and 92 cases had probable diagnosis. Among TB culture-positive cases, Xpert MTB/RIF had 100% and 81% sensitivity in sputum smear-positive and smear-negative groups, respectively. The specificity was 95.7%. The sensitivity and positive predictive value of Xpert MTB/RIF in culture-negative but clinically diagnosed PTB was 37.8% and 83.8%, respectively. Centrifugation was required in 59% cases with scanty sputum. Five cases were false-positive by Xpert MTB/RIF in patients with nontuberculous mycobacteria, old PTB scar, and immune reconstitution syndrome. Discordant rifampicin susceptibility results of Xpert MTB/RIF and mycobacteria growth indicator tube (MGIT) were confirmed by using rpoB gene sequencing, which raised the sensitivity of Xpert MTB/RIF in detecting rifampicin resistance to 93.8%. CONCLUSIONS: Xpert MTB/RIF is an effective tool in diagnosing PTB but will be more cost-effective for sputum-negative patients and in settings with high prevalence of rifampicin resistance. Early diagnosis of TB results in early treatment and implementation of strategies to limit spreading of TB. Sputum centrifugation may increase the yield of Xpert MTB/RIF.
引用
- Kawkitinarong K, Suwanpimolkul G, Kateruttanakul P, et al. Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand. Clin Infect Dis. 2017. PMID: 28475796. doi:10.1093/cid/cix151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。